Stereotactic body radiotherapy for head and neck skin cancer

•Retrospective review of head and neck skin cancer (HNSC) patients treated with stereotactic body radiation therapy (SBRT).Largest North American experience published in the modern era.•SBRT for HNSC provides durable local control rates with acceptable late toxicity rates. To report outcomes of Ster...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2021-12, Vol.165, p.1-7
Main Authors: Voruganti, Indu S., Poon, Ian, Husain, Zain A., Bayley, Andrew, Barnes, Elizabeth A., Zhang, Liying, Chin, Lee, Erler, Darby, Higgins, Kevin, Enepekides, Danny, Eskander, Antoine, Karam, Irene
Format: Article
Language:English
Subjects:
Head and Neck Neoplasms - radiotherapy
Head and neck skin cancer
Humans
Local control
Medically unfit
Progression-Free Survival
Radiosurgery - adverse effects
Retrospective Studies
Skin Neoplasms - radiotherapy
Stereotactic Body Radiation Therapy
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Retrospective review of head and neck skin cancer (HNSC) patients treated with stereotactic body radiation therapy (SBRT).Largest North American experience published in the modern era.•SBRT for HNSC provides durable local control rates with acceptable late toxicity rates. To report outcomes of Stereotactic Body Radiotherapy (SBRT) for head and neck skin cancer (HNSC) patients treated at a high-volume center. A retrospective review of HNSC SBRT patients from 2012 to 2019 was conducted. Kaplan–Meier method was used to estimate local control (LC), locoregional control (LRC) outside of SBRT field, overall survival (OS), progression-free survival (PFS) and late toxicity (LT). Univariate and multivariate analyses were performed. Grade 3-4 acute and late toxicities were reported by the Common Terminology Criteria for Adverse Events v5.0. One hundred and six medically unfit HNSC patients (112 lesions) were included. Median follow-up was 8 months. Median patient age at diagnosis was 86 years (range: 56–102 years). The majority of patients had advanced disease (overall stage III-IV [n = 90, 85%]) with median gross tumor volumes (GTV) of 31 cm3 (range: 17–56 cm3). Treated sites were: primary (n = 51), nodal (n = 47) or primary plus nodal (n = 8). SBRT doses ranged from 32-50 Gy delivered twice weekly in 4–6 fractions to the gross tumor volume (GTV). One and 2-year LC rates were 78% (69–88) and 67% (53–82), respectively. One-year LRC outside of SBRT field, OS, PFS and LT rates were 72% (62–84), 53% (43–65), 52% (40–62), and 7% (2–17), respectively. Thirty-three patients (31%) developed acute grade ≥ 3 treatment-related toxicity, most commonly dermatitis (n = 31). Nine patients (8%) experienced late grade ≥ 3 toxicity, including 7 grade 3 fibrosis, 1 grade 3 bone radionecrosis and 1 grade 4 skin ulceration. No treatment-related deaths (grade 5) were observed. SBRT provides durable disease control with acceptable toxicity for medically unfit high-risk HNSC patients unable to undergo standard of care curative treatment approaches.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2021.10.004